Aceclofenac versus piroxicam in the management of osteoarthritis of the knee: A double-blind controlled study

Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials

“…As shown in Figure 2, both sequence generation and allocation concealment were adequate in four trials (41)(42)(43)48 (41)(42)(43)(46)(47)(48). No study was deemed adequate with respect to the blinding of outcome assessment.…”

“…Ward et al (41) could not contribute in the efficacy assessment due to dichotomous data of pain and physical function, and we used this trial for the safety assessment only (41). Table 1 shows the general characteristics of all nine included trials, including study design, total number of randomized participants, gender distribution, trial duration, dose, and number of randomized patients for aceclofenac and control drugs (40)(41)(42)(43)(44)(45)(46)(47)(48). Control drugs were diclofenac in five trials (41-44, 45), piroxicam in two (46, 47), and acetaminophen (48) and naproxen (40) in one trial each.…”

Endoscopic evaluation of aceclofenac-induced gastroduodenal mucosal damage: a double-blind comparison with sodium diclofenac and placebo

“…Aceclofenac (2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid) is a novel NSAID developed by Prodesfarma in Spain. It has been marketed in several countries, including Spain, Portugal and the UK and has an established role in the treatment of rheumatoid arthritis and osteoarthritis because of its high efficacy and low potential for inducing gastropathy [2][3][4][5]. Clinical trials of this drug in Japan are now ongoing in patients with rheumatoid arthritis and osteoarthritis of the knee, and the data obtained so far indicate a much improved gastrointestinal safety profile compared to conventional NSAIDs [6,7].…”

Aceclofenac in the treatment of diseases of the locomotor apparatus

“…Показано, что препарат не уступает по эффективности при РЗ высокоэффективным в отношении боли и воспаления н-НПВП: диклофенаку, кетопрофену, индометацину, напроксену, пироксикаму [18][19][20][21][22][23][24][25]. В отече-ственном многоцентровом исследовании сравнивали эф-фективность и безопасность ацеклофенака (n=100) и дик-лофенака (n=100) у больных ОА при 3-месячном непрерыв-ном приеме.…”